X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PB2452 (bentracimab) is a novel, recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations.
Lead Product(s): Bentracimab
Therapeutic Area: Hematology Product Name: PB2452
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: SFJ Pharmaceuticals
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 17, 2023
Details:
PB2452 (bentracimab) is a novel, recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in patients who present with uncontrolled bleeding or require surgery.
Lead Product(s): Bentracimab
Therapeutic Area: Hematology Product Name: PB2452
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
Bentracimab, a human mAB antigen-binding fragment designed to reverse antiplatelet activity of ticagrelor in patients with uncontrolled bleeding, was well tolerated in Phase 2b trial, with no drug-related serious adverse event or thrombotic event reported.
Lead Product(s): Bentracimab
Therapeutic Area: Hematology Product Name: PB2452
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
Manufacturing of PB2452 (bentracimab), an mAB antigen-binding fragment drug substance, and drug product process performance qualification batch has been completed designed to reverse antiplatelet activity of ticagrelor in patients who present with uncontrolled bleeding.
Lead Product(s): Bentracimab
Therapeutic Area: Hematology Product Name: PB2452
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
Pemziviptadil, a novel, subcutaneously injected VIP analogue. Based on the pharmacokinetic profile of pemziviptadil observed in PhaseBio clinical trials, the fusion of VIP to ELP results in both a prolonged absorption profile.
Lead Product(s): Pemziviptadil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PB1046
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2021
Details:
Global Phase 3 trial of bentracimab achieved primary reversal endpoint with immediate and sustained reversal of the antiplatelet effects of ticagrelor in both surgical and bleeding population. Bentracimab appeared well tolerated with no drug-related serious adverse events.
Lead Product(s): Bentracimab
Therapeutic Area: Hematology Product Name: PB2452
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021
Details:
Treatment with bentracimab in the Phase 2b trial had a safety profile consistent with the Phase 1 and 2a trials previously completed by the company, with no drug-related serious adverse events or thrombotic events reported in the trial.
Lead Product(s): Bentracimab
Therapeutic Area: Hematology Product Name: PB2452
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2021
Details:
In conjunction with the updates regarding the Phase 3 REVERSE-IT trial, PhaseBio also announced today the completion of enrollment in the randomized, double-blind, placebo-controlled Phase 2b trial of bentracimab .
Lead Product(s): Bentracimab
Therapeutic Area: Hematology Product Name: PB2452
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2021
Details:
Bentracimab is a new human monoclonal antibody fragment which in previous clinical studies has shown an immediate and prolonged reversal of the antiplatelet effects of Brilinta® / Brilique® (ticagrelor).
Lead Product(s): Bentracimab
Therapeutic Area: Hematology Product Name: PB2452
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alfasigma
Deal Size: $245.0 million Upfront Cash: $20.0 million
Deal Type: Acquisition June 22, 2021
Details:
BioVectra will provide its integrated CDMO services for the manufacturing of the active pharmaceutical ingredient (API) of bentracimab for use in PhaseBio’s ongoing global clinical trials and for global commercial use upon regulatory approval.
Lead Product(s): Bentracimab
Therapeutic Area: Hematology Product Name: PB2452
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Biovectra Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
